position: EnglishChannel > International Cooperation > Article

Chinese scientists author article on effective COVID-19 treatment

Source: International Communication Center for Science & Technology| 2020-04-14 12:51:43| Author: Qu Jian & China.org

Written by: Qu Jian     English Version: China.org

Convalescent plasma can significantly alleviate the clinical symptoms and reduce the viral load of severe COVID-19 patients, according to a research article by Chinese scientists published April 6 in the U.S. on the latest issue of Proceedings of the National Academy of Sciences (PNAS).

China National Biotec Group (CNBG), a subsidiary of China National Pharmaceutical Group Corporation, summarized the effectiveness and safety of the convalescent plasma therapy based on the phase-one clinical trial results, and submitted the article to PNAS for publication on March 18. Titled “Effectiveness of Convalescent Plasma Therapy in Severe COVID-19 Patients,” the article introduced the rationale, effects, and adverse effects of the therapy.

According to CNBG, it prepared the convalescent plasma applicable to the clinical treatment of severe COVID-19 cases through strict biosafety tests on the blood, virus inactivation, and antiviral activity tests. The efforts were made in cooperation with hospitals, research institutes, and other companies under the support of the Ministry of Science and Technology. 

Further research will be carried out on the optimal timing and dosage of the convalescent plasma treatment, according to CNBG.

The company made plans for convalescent plasma collecting and clinical treatment, and set technical standards on Feb. 8, and saw significant improvement in the clinical manifestations of the 10 severe cases between 12 and 24 hours after the patients received the therapy.

The convalescent plasma therapy is now being used in many countries and regions worldwide.

(You can also read the article at: http://www.china.org.cn/china/2020-04/14/content_75929576.htm )

Editor:余昊原

Top News

  • At 6:57 a.m. on September 3, Air China CA746 carrying passengers from Phnom Penh, Cambodia, landed at Beijing Capital International Airport. It was the first international flight to Beijing Capital International Airport since the Civil Aviation Administration of China announced the gradual resumption of direct international flights to Beijing without passing through one of the designated first points of entry into China.

Haploid induction greatly speeds up maize breeding process

The new haploid breeding technology has significantly sped up the process of maize breeding in China, said Dai Jingrui, an academician of the Chinese Academy of Engineering (CAE) and a professor at China Agricultural University (CAU).

A Future to Expect: International S&T Community Expresses High Hope in Cooperation with Peers in China

According to the latest news from Science and Technology Daily (April 14th), two COVID-19 inactivated vaccines were just approved for a phase I & II combined clinical trial by the National Medical Products Administration (NMPA) of China, making them the first batch in this category. The two vaccines were developed respectively by Wuhan Institute of Biological Products Co., Ltd of Sinopharm and Sinovac Research & Development Co., Ltd together with research institutes.

Copyright © Science and Technology Daily, All Rights Reserved

mailto: yuhy@stdaily.com